-
provide fresh tumor specimens and PDX models, novel engineered murine models, state of the art-AI-enabled drug screening in microtumors and cancer cells, and more. Responsibilities The Clurman lab is
-
immunotherapy using cutting-edge protein engineering with directed evolution. The lab has developed therapeutics that are currently in clinical trials, such as ST-067 (a "decoy-resistant" IL-18), MDNA-11 (CD122
-
infections of varying severities. Define features of effective and ineffective antigen targets in the T cell repertoire and develop in vitro and in vivo models to test features of diverse immune specificities
-
ineffective antigen targets and develop in vitro and in vivo models to test features of diverse immune specificities. Participate and engage in institutional, division, and the lab's principal investigator's
-
T cell receptor specificity analysis, to define features of effective and ineffective antigen targets and develop in vitro and in vivo models to test features of diverse immune specificities
-
the development of novel therapies. We employ state-of-the-art techniques such as CRISPR screening, next-generation sequencing, and in vivo mouse modeling, with a focus on prostate cancer as a model system. Our lab